SWKH SWK Holdings Corp
FY2024 10-K
SWK Holdings Corp (SWKH) filed its fiscal year 2024 10-K annual report with the SEC on Mar 20, 2025. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2024 10-K
Business Overview
- • Core business model: dual segments of specialty finance in life sciences and pharmaceutical development/manufacturing
- • Pharmaceutical Development segment entered asset sale process with March 2024 exclusive option to sell Enteris BioPharma assets by January 2026, classified as held for sale as of Dec 31, 2024
Management Discussion & Analysis
- • Revenue $45.0M, up $7.2M YoY; Finance Receivables $4.8M increase, Pharmaceutical Development $2.4M increase
- • Net income $13.5M, down $2.4M YoY; interest expense rose to $4.7M from $1.8M; provision for credit losses increased to $12.8M
Risk Factors
- • Regulatory risk: LIBOR transition impacted by the Adjustable Interest Rate (LIBOR) Act of 2022, with synthetic U.S. dollar LIBOR continuing until September 2024
- • Macroeconomic risk: Silicon Valley Bank closure by California Department of Financial Protection and Innovation on March 10, 2023, impacting financial services liquidity
Financial SummaryXBRL
Revenue
$4M
Net Income
$13M
Operating Margin
320.4%
Net Margin
373.0%
ROE
4.7%
Total Assets
$332M
EPS (Diluted)
$1.08
Operating Cash Flow
$23M
Source: XBRL data from SWK Holdings Corp FY2024 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on SWK Holdings Corp
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.